1. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.
- Author
-
Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, Little LD, Qiu P, Bertelsen AH, Watson M, Warner A, Muir AJ, Brass C, Albrecht J, Sulkowski M, McHutchison JG, and Goldstein DB
- Subjects
- Alleles, Anemia, Hemolytic complications, Antiviral Agents, Chromosomes, Human, Pair 20, Europe ethnology, Genome-Wide Association Study, Hemoglobins deficiency, Hemoglobins metabolism, Hepatitis C, Chronic complications, Humans, Polymorphism, Single Nucleotide genetics, Pyrophosphatases deficiency, Pyrophosphatases metabolism, Racial Groups genetics, Ribavirin therapeutic use, United States, Inosine Triphosphatase, Anemia, Hemolytic chemically induced, Anemia, Hemolytic genetics, Genetic Variation genetics, Hepatitis C, Chronic drug therapy, Pyrophosphatases genetics
- Abstract
Chronic infection with the hepatitis C virus (HCV) affects 170 million people worldwide and is an important cause of liver-related morbidity and mortality. The standard of care therapy combines pegylated interferon (pegIFN) alpha and ribavirin (RBV), and is associated with a range of treatment-limiting adverse effects. One of the most important of these is RBV-induced haemolytic anaemia, which affects most patients and is severe enough to require dose modification in up to 15% of patients. Here we show that genetic variants leading to inosine triphosphatase deficiency, a condition not thought to be clinically important, protect against haemolytic anaemia in hepatitis-C-infected patients receiving RBV.
- Published
- 2010
- Full Text
- View/download PDF